Provectus net loss narrows 46.6% to $988,716 in Q2 FY26
PVCT•Quarterly loss narrows
Provectus Biopharmaceuticals posted a net loss of $988,716, narrowing 46.6% from a year earlier.
Operating loss narrowed 47.9% to $938,678 as total operating expenses fell 49.5% to $938,678.
Cash position and going-concern risk
Cash rose to $1.16 million at June 30, 2026; working capital deficit was $6.34 million, with substantial doubt about going concern.
Expenses decline on reduced clinical activity
Research and development expense dropped 85.1% to $131,130 on reduced clinical activity, including manufacturing and development work.
General and administrative costs declined 17.4% to $807,548, partly offset by higher insurance and software license renewals.
